| Literature DB >> 30021655 |
Meng Liu1, Shubin Jiang2, Yu Ma3, Jun Ma2, Waseem Hassan4, Jing Shang5,6.
Abstract
BACKGROUND: Alterations in gene expression in peripheral blood cells play a curtail role in the presence and extent of coronary artery disease (CAD), but its severity reflected by gene expression alterations in peripheral blood cells is still unknown in Xinjiang population in China.Entities:
Keywords: Coronary artery disease; Coronary stenosis; Genetic variation; Microarray analysis; Toll-like receptor signaling pathway
Mesh:
Substances:
Year: 2018 PMID: 30021655 PMCID: PMC6052538 DOI: 10.1186/s12944-018-0798-1
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Fig. 1Schematic overview of the workflow. Peripheral blood were obtained from 9 control groups and 21 CAD patients who underwent angiography. In the study, controls were defined by coronary angiography as 0% stenosis and mild CAD as 25% ~ 50% stenosis, moderate CAD as 50% ~ 70% stenosis, severe CAD as ≥75% stenosis
Clinical characteristics of control group and the extent of coronary artery disease patients
| Control group | Mild stenosis group | Moderate stenosis group | Severe stenosis group |
| |
|---|---|---|---|---|---|
| Age ± sd (years) | 43.66 ± 5.61 | 50.36 ± 4.31 | 52.66 ± 5.19 | 50.16 ± 5.36 | 0.772 |
| BMI ± sd (kg/m2) | 23.20 ± 2.52 | 25.20 ± 2.52 | 26.50 ± 1.92 | 28.13 ± 3.36 | 0.640 |
| Hx of Hyperlipidemia ( | 0 | 2 (33%) | 4 (66%) | 6 (66%) | 0.541 |
| Hx of Hypertension ( | 0 | 2 (33%) | 3 (50%) | 4 (44%) | 0.813 |
| Hx of Diabetes ( | 0 | 0 | 0 | 0 | |
| Hx of Smoking ( | 2 (22%) | 3 (50%) | 3 (50%) | 8 (88%) | 0.750 |
| Coronary arterial stenosis ( | 0 | 39 ± 4% | 67 ± 5% | 81 ± 6% | <0.001 |
| LV ejection fraction (%) | 50.7 ± 1% | 55.76 ± 2% | 59.16 ± 2% | 62.1 ± 4% | 0.780 |
| Biometrics | |||||
| Systolic blood pressure ± sd (mmHg) | 118.88 ± 6.00 | 120.38 ± 9.39 | 122.33 ± 6.00 | 138.4 ± 8.93 | 0.813 |
| Diastolic blood pressure ± sd (mmHg) | 75.55 ± 7.26 | 71 ± 3.22 | 77.44 ± 8.09 | 87.9 ± 4.22 | 0.731 |
| Laboratory parameterst | |||||
| Total cholesterol ± sd (mmol/L) | 3.67 ± 0.34 | 3.77 ± 0.45 | 3.99 ± 0.34 | 4.2 ± 1.19 | 0.042 |
| LDL-cholesterol ± sd (mmol/L) | 2.19 ± 0.38 | 2.91 ± 0.58 | 2.98 ± 0.71 | 3.25 ± 0.77 | 0.087 |
| HDL-cholesterol ± sd (mmol/L) | 1.94 ± 0.91 | 1.11 ± 0.25 | 1.24 ± 0.21 | 1.09 ± 0.45 | 0.083 |
| Triglycerides (mmol/L) | 1.03 ± 0.45 | 1.64 ± 0.45 | 2.64 ± 0.45 | 3.07 ± 0.85 | 0.032 |
| Apolipoprotein A (g/L) | 1.16 ± 0.06 | 1.61 ± 0.06 | 1.96 ± 0.06 | 2.15 ± 0.31 | 1 |
| Apolipoprotein B (g/L) | 0.76 ± 0.06 | 1.09 ± 0.06 | 1.29 ± 0.08 | 1.99 ± 0.25 | 1 |
| HbAIC ( | 4.45 ± 0.46 | 5.65 ± 0.36 | 5.97 ± 0.46 | 6.01 ± 0.87 | 0.431 |
| Hs-CRP (mg/L) | 4.34 ± 0.14 | 3.506 ± 0.14 | 3.906 ± 0.14 | 4.106 ± 1.00 | 0.866 |
| Hematocrit (HCT) | 4.13 ± 0.23 | 4.31 ± 0.13 | 4.33 ± 0.32 | 4.79 ± 0.15 | 0.753 |
| Creatinine (mg/dL) ( | 73.13 ± 11.17 | 76.13 ± 10.17 | 78.13 ± 13.17 | 76.34 ± 12.25 | 0.201 |
| White blood cell count (109/L) | 6.12 ± 1.12 | 6.92 ± 1.21 | 7.12 ± 1.32 | 8.02 ± 2.26 | 0.567 |
| Medications | |||||
| Statins ( | 0 | 3 (50%) | 4 (66%) | 7 (77%) | 0.850 |
Fig. 2Hierarchical cluster analysis of differentially expressed genes. Differentially expressed genes as identified by the Gene spring software are represented in rows, and the different samples are represented in columns. Red indicates relative overexpression while green represent relative underexpression level, Black values represent central expression values
Fig. 3Genes expression patterns in the differential coronary artery stenosis patients. a gradually downregulated genes from control group to severe coronary artery stenosis group. b gradually upregulated genes from control group to severe coronary artery stenosis group
Fig. 4Functional annotation of differentially expressed genes. a Enrichment analysis for the same gene ontology categories in GO terms derived from downregulated genes. b GO functional networks of downregulated genes, Color of node represented significantly GO terms. c Enrichment analysis for the same gene ontology categories in GO terms derived from upregulated genes. d GO Functional networks of upregulated genes, Color of node represented significantly GO terms
Fig. 5KEGG pathway enrichment analysis results. a KEGG pathways mediated by gradually downregulated genes. b KEGG Pathways mediated by gradually upregulated genes
12 differentially expressed genes associated with toll-like receptor signaling pathway in the extent of coronary artery stenosis patients
| Gene symbol | Gene description | Trend 1 | Trend 2 | Trend 3 | |
|---|---|---|---|---|---|
| MAPK3 | Mitogen-activated protein kinase 3 | 0.1681 | 0.3593 | 0.9498 | 0.00045 |
| MAPK1 | Mitogen-activated protein kinase 1 | 0.2921 | 0.5725 | 1.1005 | 0.00196 |
| CHUK | Conserved helix-loop-helix ubiquitous kinase | 0.1854 | 0.2862 | 0.6197 | 0.00622 |
| PIK3CB | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | 0.4401 | 0.4743 | 1.1232 | 0.00830 |
| MAPK14 | Mitogen-activated protein kinase 14 | 0.3399 | 0.7724 | 1.9161 | 0.00960 |
| TLR4 | Toll like receptor 4 | 0.6287 | 0.8780 | 1.9592 | 0.01065 |
| IFNAR1 | Interferon alpha and beta receptor subunit 1 | 0.3049 | 0.9418 | 1.0834 | 0.01283 |
| MAPK13 | Mitogen-activated protein kinase 13 | 0.1807 | 0.3373 | 0.7193 | 0.02156 |
| JUN | Jun proto-oncogene | 0.3740 | 0.4746 | 1.0779 | 0.02579 |
| TLR2 | Toll like receptor 2 | 0.2299 | 0.4885 | 1.2470 | 0.03053 |
| MYD88 | Myeloid differentiation primary response 88 | 0.4350 | 0.6164 | 0.8260 | 0.03805 |
| IRAK4 | Interleukin 1 receptor associated kinase 4 | 0.0101 | 0.3213 | 0.7935 | 0.04165 |
Trend 1: Mid CAD compared with control group; Trend 2: Moderate CAD compared with mid group; Trend 3: Severe CAD compared with moderate group
Fig. 6ROC analysis. Twelve genes associated with toll-like receptor signaling pathway were validated by ROC analysis in 236 CAD patients from GEO dataset. The AUC was 0.67 ± 0.037, and sensitivity was 77.65% and specificity was 51.52%